Steven de Jong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/398069/publications.pdf

Version: 2024-02-01

257450 361022 2,397 36 24 35 citations g-index h-index papers 38 38 38 5241 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	28.4	527
2	Metformin: Taking away the candy for cancer?. European Journal of Cancer, 2010, 46, 2369-2380.	2.8	345
3	TRAIL receptor signalling and modulation: Are we on the right TRAIL?. Cancer Treatment Reviews, 2009, 35, 280-288.	7.7	248
4	Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. Journal of Clinical Investigation, 2010, 120, 3594-3605.	8.2	193
5	MAPK pathway activity plays a key role in PD‣1 expression of lung adenocarcinoma cells. Journal of Pathology, 2019, 249, 52-64.	4.5	117
6	Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treatment Reviews, 2020, 88, 102054.	7.7	76
7	ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene, 2018, 37, 4611-4625.	5.9	72
8	ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 176-184.	7.4	69
9	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resistance Updates, 2016, 24, 55-69.	14.4	52
10	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2016, 22, 714-724.	7.0	51
11	Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. Frontiers in Immunology, 2019, 10, 1530.	4.8	51
12	Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Medicine, 2017, 15, 116.	5 . 5	44
13	Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. Scientific Reports, 2015, 5, 14495.	3.3	41
14	Practical Implications of Metacognitively Oriented Psychotherapy in Psychosis. Journal of Nervous and Mental Disease, 2016, 204, 713-716.	1.0	41
15	Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer, 2017, 17, 232.	2.6	40
16	Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. Cancer Letters, 2019, 461, 102-111.	7.2	40
17	Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene, 2004, 23, 4862-4872.	5 . 9	39
18	miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy. Cells, 2019, 8, 1221.	4.1	39

#	Article	IF	Citations
19	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer ¹⁸ F-BMS-986192. Journal of Nuclear Medicine, 2020, 61, 1839-1844.	5.0	37
20	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clinical Cancer Research, 2018, 24, 3928-3940.	7.0	35
21	Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Genome Medicine, 2016, 8, 107.	8.2	31
22	Avenues to molecular imaging of dying cells: Focus on cancer. Medicinal Research Reviews, 2018, 38, 1713-1768.	10.5	30
23	Targeting <scp>FLIP</scp> and Mclâ€1 using a combination of aspirin andÂsorafenib sensitizes colon cancer cells to <scp>TRAIL</scp> . Journal of Pathology, 2013, 229, 410-421.	4.5	28
24	Molecular Imaging As a Tool for Drug Development and Trial Design. Journal of Clinical Oncology, 2015, 33, 2585-2587.	1.6	27
25	ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells. Oncotarget, 2017, 8, 45432-45446.	1.8	23
26	Targeting Trail Towards the Clinic. Current Drug Targets, 2011, 12, 2079-2090.	2.1	21
27	⁸⁹ Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. MAbs, 2017, 9, 1370-1378.	5.2	20
28	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. Oncotarget, 2016, 7, 68111-68121.	1.8	16
29	Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models. Cancers, 2019, 11, 895.	3.7	12
30	Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and <i>in vivo</i> Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets. Theranostics, 2017, 7, 482-492.	10.0	10
31	Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment. Molecular Cancer Therapeutics, 2020, 19, 590-601.	4.1	8
32	Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities. International Journal of Molecular Sciences, 2022, 23, 3745.	4.1	6
33	Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies. Scientific Reports, 2020, 10, 18938.	3.3	4
34	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. PLoS ONE, 2020, 15, e0235766.	2.5	2
35	Satisfaction with social connectedness as a predictor for positive and negative symptoms of psychosis: A PHAMOUS study. Schizophrenia Research, 2021, 238, 121-127.	2.0	2
36	Abstract 5813: Glycogen synthesis as potential novel target in triple negative breast cancer: Glycogen synthase 1 expression in human breast cancers and the impact of downregulation on proliferation of preclinical models. Cancer Research, 2022, 82, 5813-5813.	0.9	O